World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
53681
World Ranking
8427
National Ranking
121

Javier Cortes publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Javier Cortes sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 577 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Javier Cortes D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Javier Cortes sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Javier Cortes is affiliated with Vall d'Hebron Hospital Universitari in Spain and has published extensively in the medical field, particularly focusing on oncology and breast cancer research.

Their research primarily spans the fields of Medicine, with 1,148 publications, and Biochemistry, Genetics, and Molecular Biology, covering 293 works. Key subfields include Oncology (655 publications), Pulmonary and Respiratory Medicine (295), Cancer Research (202), Radiology, Nuclear Medicine and Imaging (88), and Molecular Biology (63). This range highlights a broad engagement with clinical and molecular aspects of cancer research.

The main topics explored in their work include:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

Among their frequent co-authors are Antonio Llombart-Cussac, Hope S. Rugo, José Manuel Pérez-García, Giuseppe Curigliano, and Peter Schmid, indicating a collaborative research network in oncology and breast cancer treatment.

Javier Cortes has contributed to several notable papers, including:

  • "Pembrolizumab for Early Triple-Negative Breast Cancer" (2020) published in New England Journal of Medicine
  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020) published in The Lancet
  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021) published in New England Journal of Medicine
  • "5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)" (2020) published in Annals of Oncology
  • "ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer" (2021) published in Annals of Oncology

The most frequent publication venues for Javier Cortes include Cancer Research, Annals of Oncology, Journal of Clinical Oncology, ESMO Open, and Clinical Cancer Research, reflecting a focus on cancer and oncology-centric journals.

In addition to research articles, they have contributed to book publications such as "Por una nueva historia de la familia en México" (2024) published by Universidad Autónoma de Aguascalientes eBooks.

Best Publications

  • Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    José Baselga;Javier Cortés;Sung-Bae Kim;Seock-Ah Im

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

    A. Schneeweiss;S. Chia;T. Hickish;V. Harvey

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

    Maurizio Scaltriti;Federico Rojo;Alberto Ocaña;Judit Anido

  • Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

    José Baselga;Karen A. Gelmon;Shailendra Verma;Andrew Wardley

  • Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

    Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Regina Mayor;Charlotte K. Y. Ng;Britta Weigelt

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

    Maria Teresa Herrera-Abreu;Marta Palafox;Uzma Asghar;Martín A Rivas

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

    Yasir H. Ibrahim;Celina García-García;Violeta Serra;Lei He

  • Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    José Baselga;Seock Ah Im;Hiroji Iwata;Javier Cortés

  • The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Luping Lin;Amit J Sabnis;Elton Chan;Victor Olivas

Frequent Co-Authors

José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Véronique Diéras
Véronique Diéras Institute Curie
Aleix Prat
Aleix Prat University of Barcelona
Paolo Nuciforo
Paolo Nuciforo Vall d´Hebron Institute of Oncology
Joan Seoane
Joan Seoane Institució Catalana de Recerca i Estudis Avançats

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine isn’t limited to the traditional path of becoming a physician. Many related healthcare degrees and career options are available online, offering flexible entry points and faster progression for those seeking to make a difference in healthcare.

For experienced nurses aiming to reach the highest levels of clinical nursing practice, shortest dnp programs provide a streamlined way to earn a Doctor of Nursing Practice in less time. Those who prefer manageable coursework can consider easiest online dnp programs, which balance academic rigor with supportive learning environments.

Entry-level options like lpn programs are ideal for those who want to quickly begin working in the medical field as Licensed Practical Nurses. Meanwhile, for nurses interested in mental health, accelerated msn psychiatric np programs offer a fast track to becoming a specialized nurse practitioner.

Each of these online pathways offers a unique route to impactful, rewarding medical careers for diverse backgrounds and goals.

Best Scientists Citing Javier Cortes

Trending Scientists

Recently Published Articles